Open Payments

ELIZABETH A MICKS

Type
Physician · Allopathic & Osteopathic Physicians / Obstetrics & Gynecology
Where
ARCATA, CA
NPI
1144405119
Received
$2,817 in 6 records, 2019 to 2023
As principal investigator
$191,361 of research payments to others in 34 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment1$17
2022General payment1$13
2020General payment1$1,375
2019General payment3$1,411

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC3$2,3862019–2020
Bayer Healthcare Pharmaceuticals Inc.1$4002019
Sumitomo Pharma America, Inc.1$172023
PFIZER INC.1$132022

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v3$2,775
Food and Beverage3$42

Records

DateCompanyAmountNatureFormProductStudyYear
2023-03-08Sumitomo Pharma America, Inc.$17Food and BeverageIn-kind items and servicesMYFEMBREE Drug, HORMONE THERAPY2023
2022-10-05PFIZER INC.$13Food and BeverageIn-kind items and servicesPREMARIN Drug, WOMENS HEALTH2022
2020-06-12Merck Sharp & Dohme LLC$1,375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNEXPLANON Drug, WOMENS HEALTH2020
2019-08-12Bayer Healthcare Pharmaceuticals Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKyleena Drug, Women's Health2019
2019-01-28Merck Sharp & Dohme LLC$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNEXPLANON Drug, WOMENS HEALTH2019
2019-01-28Merck Sharp & Dohme LLC$11Food and BeverageIn-kind items and servicesNEXPLANON Drug, WOMENS HEALTH2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2023-03-16Sebela Women's Health Inc.University Of Washington Med Ctr$2,729A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2023
2023-03-16Sebela Women's Health Inc.University Of Washington Med Ctr$1,941A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2023
2023-02-02Sebela Women's Health Inc.University Of Washington Med Ctr$1,294A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2023
2022-12-28Sebela Women's Health Inc.University Of Washington Med Ctr$1,294A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-10-13Sebela Women's Health Inc.University Of Washington Med Ctr$1,294A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-09-15Sebela Women's Health Inc.University Of Washington Med Ctr$2,588A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-06-16Sebela Women's Health Inc.University Of Washington Med Ctr$2,168A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-05-26Sebela Women's Health Inc.University Of Washington Med Ctr$2,581A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-04-27Sebela Women's Health Inc.University Of Washington Med Ctr$12,378A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-02-17Sebela Women's Health Inc.University Of Washington Med Ctr$1,435A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2022-01-27Sebela Women's Health Inc.University Of Washington Med Ctr$2,043A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2022
2021-12-22Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$499A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2021
2021-12-22Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$2,065A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2021
2021-11-24Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$4,268A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2021
2021-10-21Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$647A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2021
2021-09-29Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$1,623A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2021
2020-11-13Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$1,123A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-11-13Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$1,508A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-10-16Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$4,954A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-09-18Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$4,336A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-08-21Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$3,984A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-07-14Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$5,599A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-06-18Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$3,433A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-05-28Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$4,743A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-05-14Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$1,453A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-05-14Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$7,231A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-04-23Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$6,572A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2020-03-09Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$3,644A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU2020
2019-12-16Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$14,750A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau2019
2019-11-25Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$7,741A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau2019
2019-11-04Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$38,610A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau2019
2019-09-06Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$10,010A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau2019
2019-07-26Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$22,155A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau2019
2019-06-28Sebela Pharmaceuticals Inc.UNIVERSITY OF WASHINGTON MED CTR$8,655A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Humboldt CountyArcata city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Arcata, CA, county Humboldt County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Arcata, CA
County
Humboldt County, CA
State
California
Population B0100318,607134,54139,287,377
Population, 2020 census P118,857136,46339,538,223
Median age B0100228.139.937.9
Under 18 B0100111.8%18.8%22.0%
65 and over B0100114.2%19.8%15.7%
Households B110017,88454,92213,548,091
Foreign born B050024.6%6.2%27.0%
Median household income B19013$46,713$61,160$99,122
Median family income B19113$91,661$83,067$113,346
Per capita income B19301$32,307$36,080$49,513
Poverty rate B1700127.2%18.7%12.0%
Unemployment rate B2302511.9%9.0%6.6%
Civilian labor force B2302510,54163,65920,068,466
Mean commute (minutes) B0801317.819.028.7
Bachelor's degree or higher B1500346.3%33.1%37.1%
Housing units B250018,63662,88314,644,735
Owner-occupied B2500336.4%56.5%55.9%
Renters B2500363.6%43.5%44.1%
Median home value B25077$484,600$446,900$734,700
Median gross rent B25064$1,327$1,287$2,036
White, not Hispanic B0300270.6%69.5%33.8%
Black B030023.0%1.3%5.2%
Hispanic or Latino B0300216.0%14.2%40.2%
Asian B030021.1%3.0%15.3%
American Indian and Alaska Native B030020.8%3.1%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Arcata, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.